The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. Here, we examined its effects on multiple myeloma (MM) cells and found that, at 500 nM, it potently inhibited growth and induced apoptosis in 2 of 8 MM cell lines. RNA from un-treated and DZNep treated cells was profiled by Affymetrix HG-U133 Plus 2.0 microarray and genes with a significant change in gene expression were determined by significance analysis of microarray (SAM) testing. ALOX5 was the most down-regulated gene (5.8-fold) in sensitive cells and was expressed at low level in resistant cells. The results were corroborated by quantitative RT-PCR. Western-blot analysis indicated ALOX5 was highly expressed only in sensitive cell line H929 and greatly decreased upon DZNep treatment. Ectopic expression of ALOX5 reduced sensitivity to DZNep in H929 cells. Furthermore, down-regulation of ALOX5 by RNA interference could also induce apoptosis in H929. Gene expression analysis on MM patient dataset indicated ALOX5 expression was significantly higher in MM patients compared to normal plasma cells. We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. Taken together, this study shows one of mechanisms of the DZNep efficacy on MM correlates with its ability to down-regulate the ALOX5 levels. In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. These results suggest that DZNep may be exploited therapeutically for a subset of MM.
Citation: Xie Z, Bi C, Cheong LL, Liu SC, Huang G, Zhou J, et al. (2011) Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells. PLoS ONE 6(6): e21583. https://doi.org/10.1371/journal.pone.0021583
Editor: Venugopalan Cheriyath, Cleveland Clinic, United States of America
Received: February 10, 2011; Accepted: June 3, 2011; Published: June 24, 2011
Copyright: © 2011 Xie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project is funded by the National Medical Research Council of Singapore (http://www.nmrc.gov.sg/) grant NMRC/CG/NCIS/2010. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
The 3-Deazaneplanocin A (DZNep) is the cyclopentanyl analog of 3-deazaadenosine that inhibits the activity of S-adenosyl-L homocysteine (AdoHcy) hydrolase, the enzyme responsible for the reversible hydrolysis of AdoHcy to adenosine and homocysteine , . Inhibition of AdoHcy hydrolase results in the cellular accumulation of AdoHcy, which leads to inhibition of S-adonosyl-L-methionine-dependent methyltransferase (MTase) activity. DZNep has been explored for antiviral treatment and has been reported to have minimal toxicity in vivo , , . Recently, DZNep was reported to decrease levels of the PRC2 protein complex in breast cancer cells and inhibit associated histone H3K27Me3. It induced efficient apoptotic cell death in cancer cells but not in normal cells . DZNep was also shown to deplete PRC2 complex, decrease levels of H3K27Me3, and induce apoptosis of cultured and primary acute myeloid leukemia (AML) cells. Furthermore, cotreatment with DZNep and the pan-histone deacetylase inhibitor panobinostat induced synergistic apoptosis of cultured and primary AML cells . These make DZNep a possible candidate as an epigenetic therapeutic for the treatment of cancer.
Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for 0.8% of all cancers worldwide. Incidence rates vary from 0.4 to 5 per 100 000, and is high in North America, Australia/New Zealand, northern Europe, and western Europe compared with Asian countries . Median survival for patients with MM after conventional treatments is 3–4 years; high-dose treatment followed by autologous stem-cell transplantation can extend median survival to 5–7 years . As such, the development of innovative therapies and identification of more effective drugs remain high priorities for MM research. Because of its antitumor properties, DZNep holds promise as a treatment for MM. To advance DZNep as anticancer agents, it is crucial to understand the molecular mechanism and delineate markers that identify the subset of tumors that are sensitive to DZNep-induced apoptosis. In the study described here, we assayed a panel of MM cell lines and showed that DZNep at low nanomolar concentratins potently induced apoptosis in some of MM cell lines. We further investigated the mechanisms of DZNep-induced apoptosis in MM cells.
Materials and Methods
Cell lines and cell culture
Human MM cell lines KMS11, KMS12BM, KMS18, MM.1S, RPMI-8226, OPM-2, U266 were maintained in RPMI 1640, supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin. MM cell line NCI-H929 was cultured in RPMI 1640 with 15% FCS and 0.00036% 2-mercaptoethanol. All cells were grown at 37 °C in a humidified atmosphere with 5% CO2. All cells were gifts from Mayo clinic, Scottsdale, AZ.
DZNep was kindly provided by Prof. Yu Qiang, Genome Institute of Singapore. The ABT-737, a Bcl-2 family inhibitor, was kindly provided by Prof. Chen Chien-Shing, Loma Linda University, CA. DZNep or ABT-737 was dissolved in neat DMSO (Sigma-Aldrich ) at 10 mmol/L and stored as frozen aliquots at −20°C. Caspase Inhibitor Z-VAD-FMK (Promega) was dissolved in DMSO and stored at −20°C.
Cell proliferation assay and apoptosis analysis
Cells were seeded into 96-well plates at a density of 3.0×104 cells/well in 50 µL culture medium. Then,50 µL of doubly concentrated drug solutions was added. Cells were incubated at 37°C in a humidified, 5% CO2 atmosphere for 72 h, and subsequently analyzed using the MTS colorimetric assay (Promega) as previously described . The combination index (CI) for DZNep and ABT-737 combination was obtained using software CalcuSyn as described previously . A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively. For apoptosis analysis, cells were treated with 0.5 µM DZNep and cultured for 72 h. Then, cells were pooled and analyzed for the level of apoptosis by flow cytometry using propidium iodide (PI) staining as described previously , .
Microarray analysis and quantitative RT-PCR
Cells were treated with 0.5 µmol/L DZNep for 48 h. Total RNA was extracted by using the Qiagen RNeasy Mini kit (Germany). Gene expression was performed using the GeneChip® Human Genome U133A Array (Affymetrix) following the manufacturer's instructions. Data analysis was performed using GeneSpring software from Agilent Technologies. The data was deposited in Gene Expression Omnibus with accession no. GSE26921. The differentially expressed genes were grouped using Panther Protein Classification . Using oligo(dT)20 primer and reverse transcriptase, cDNA was created by using the Invitrogen SuperScript III First-Strand Synthesis System. The 7300 Real-Time PCR System (Applied Biosystems, CA) was used for real-time PCR amplification according to the Power SYBR® Green PCR Master Mix protocol. Relative quantification of gene expression was done as described in the manual using β-Actin as an internal standard and the comparative threshold cycle method. The primers for real-time PCR were listed in Table S1.
Cells were treated with 0.5 umol/L DZNep for 72 h. Cells were collected and lysed in RIPA buffer as described previously. Equal amounts of protein were separated on SDS–polyacrylamide gels and transferred to PVDF membranes. The blots were probed with antibodies against EZH2 (#3147), Cleaved Caspase-3 (Asp175) (#9661), Caspase-8 (#9746) and Caspase-9 (#9508) from Cell Signaling Technology. Antibodies against Bcl-2 (sc-509), PARP (sc-8007), H3 (sc-10809) and β-Actin (sc-69879) were from Santa Cruz Biotechnology. The antibody against ALOX5 (#160402) was from Cayman Chemical. The antibody against H3K27Me3 (#07-449) was from Millipore. Western Blotting Luminol Reagent (sc-2048) was used for detection on film from Santa Cruz Biotechnology.
Methylcellulose colony formation assay
Methylcellulose media (H4230, MethoCult®, StemCell Technologies) consisted of 1% methylcellulose, 30% fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin, and 1% bovine serum. Cells were plated in duplicate at a density of 1,500 or 3,000 cells/mL in 0.4 mL volume in 24-well plates. Plates were incubated at 37°C, 5% CO2, and ≥95% humidity (provided by a water dish) for 14 days. To observe colonies, cells were stained with 0.5 mg/mL metabolizable tetrazolium salt (MTT, M2003, Sigma-Aldrich), 100 µL/well. After incubating at 37°C, 5% CO2 for 1 h, colonies of more than 30 cells were counted. For photomicrographs, plates were viewed with an Olimpus IX71 inverted microscope at 40X magnification. Images were acquired using a digital camera DP71 and software DP Controller.
Analysis of ALOX5 expression in MM patient samples
The ALOX5 expression analysis was performed on a large gene expression dataset from the University of Arkansas Medical School that is available through the Gene Expression Omnibus. Raw expression value was obtained from GEO GSE 2658 and 5900. The expression values for probes representing ALOX5 on the U133plus 2.0 chip were first log-transformed and median centered, and then a composite relative expression value for ALOX5 for each of patients was obtained by taking the median expression across these probes. The expression value of 22 normal plasma cells (NPC) and 351 newly diagnosed MM was analyzed. The mean+2 standard deviation (SD) was used as the upper limit of normal expression.
Sequences encoding short hairpin RNA (shRNA) were cloned into pLKO.1 vector (gift of Prof. Robert A. Weinberg, Whitehead Institute for Biomedical Research, Cambridge, MA). The shRNA against ALOX5(shALOX5) sequence: 5′ ATCCAGCTGGTCAGAATCGAGAA 3′. The shRNA against Bcl-2 sequences: sh#82, 5′ CATTATAAGCTGTCGCAGAGG 3′; sh#83, 5′ TGTGGATGACTGAGTACCTGA 3′. The control shRNA against luciferase (shLuc) is from Prof. Robert A Weinberg. The sequence encoding ALOX5 was amplified from NCI-H929 and cloned into pLN1 vector (derived from pLKO.1 by replacing U6 promoter with CMV promoter). All clones were verified by sequencing.
Virus production and infection
Lentivirus infection was performed as previously described. Briefly, lentiviruses were produced by transiently cotransfecting 293T cells with the shRNA-expressing lentivirus vector, packaging plasmid pCMV-dR8.2 dvpr and VSV-G envelope plasmid pCMV-VSVG (gifts of Prof. Robert A. Weinberg) using Fugene 6 (Roche Diagnostics) according to the manufacturers' instructions. Cells were infected with lentiviruses in the presence of 8 µg/mL polybrene (Sigma-Aldrich). The NCI-H929 cell line overexpressing ALOX5 was generated using puromycin (3 µg/ml, Sigma-Aldrich) selection.
MM cell lines display differing degree of sensitivity to DZNep
To determine the sensitivity to DZNep, cells were treated with different concentrations of DZNep, and cell proliferation was measured by MTS colorimetric assay (Fig. 1A). Using this approach, NCI-H929 and MM.1S, 2 of the 8 cell lines tested, were very sensitive to DZNep-induced growth inhibition in the nanomolar range. Cell apoptosis induced by DZNep was determined by subdiploid DNA content analysis using flow cytometry. Sub-G1 fraction undergoing apoptosis was significantly increased after DZNep treatment in NCI-H929 and MM.1S, while a minor to moderate increase in apoptosis was observed in the relatively insensitive cell lines. (Fig. 1B). Because there are MM cell lines that are both sensitive and insensitive to DZNep, we had the opportunity to examine the molecular mechanisms of sensitivity to DZNep within a similar tumor type.
(A) Cells were treated with various concentrations of DZNep for 72 h. The proliferation was determined by MTS colorimetric assay (Promega). Data represent the mean ± SD derived from 3 separate experiments with triplicate wells per condition. (B) Cells were treated with 0.5 µM DZNep for 72 h, and apoptosis was measured by flow cytometric sub-G1 analysis. Data represent the mean ± SD derived from 3 separate experiments (one time for KMS12BM). * indicates p<0.05, and ** indicates p<0.01.
ALOX5 is differentially expressed in MM cells according to DZNep sensitivity
Two sensitive MM cell lines (MM.1S and NCI-H929) and two relatively insensitive MM cell lines (KMS18 and OPM-2) were profiled on cDNA microarrays after exposure to vehicle control or DZNep. Many more transcripts were differentially expressed in response to DZNep in sensitive cell lines than in insensitive cell lines (Fig. S1A, Tables S2, S3, S4). Seventy-three genes were significantly up-regulated and 113 genes were significantly down-regulated in both of the sensitive cell lines. Gene ontology analysis revealed that these genes were remarkably enriched for their roles in cellular metabolism (Fig. S1B), suggesting cellular metabolism may play a vital role in MM cell sensitivity to DZNep induced apoptosis. The arachidonate 5-lipoxygenase (ALOX5) was among the genes most down-regulated by DZNep treatment (Fig. 2A). ALOX5 has previously been linked to leukemia stem cells and cancer-related signaling pathways , , , , . The differential expression of ALOX5 indicates a potential role in determining sensitivity to DZNep in MM. Differential expression of ALOX5 was confirmed by quantitative RT-PCR (Fig. 2B). The magnitude of decreased expression of ALOX5 is similar in MM.1S and NCI-H929, but baseline levels of ALOX5expression are higher in NCI-H929 compared with MM.1S.
Cells were treated with 0.5 µmol/L DZNep for 48 h. Total RNA was extracted using the Qiagen RNeasy Mini kit. (A) The cDNA microarray analysis was done to evaluate gene expression changes in response to DZNep treatment. Heat map showed the relative expression levels of the top 20 probe sets that were differentially expressed between DZNep-sensitive and DZNep-insensitive MM cell lines. ALOX5 was most down-regulated in DZNep-sensitive cell lines. Red, relatively high expression; green, relatively low expression. (B) Quantitative levels of differentially expressed ALOX5. The ALOX5 was determined by quantitative RT-PCR. Colunms, mean; bars, SE. Average CT values were first normalized against the housekeeping gene β-Actin and converted to the induced fold change relative to the vehicle control.
DZNep reduces EZH2 and ALOX5 levels, and induces caspase-dependent cell apoptosis
DZNep treatment has been demonstrated to decrease levels of EZH2 in solid tumors and acute myeloid leukemia, . Consistent with these reports, treatment with DZNep also reduced protein levels of EZH2 in NCI-H929, MM.1S, KMS18 and OPM-2 (Fig. 3 A). H3K27Me3 levels were also decreased in KMS18 and OPM-2 but not in the two sensitive cell lines, suggesting that the induction of cell death by DZNep in myeloma cells is not mediated through its effect on EZH2 or H3K27Me3. This result also suggests that proteins other than EZH2 may be responsible for the H3K27 trimethylation. Consistent with real-time PCR results, ALOX5 was over-expressed in NCI-H929 and decreased greatly by DZNep treatment on western blot. The other 3 cell lines had low levels of ALOX5 which was also decreased by DZNep.
DZNep reduced EZH2 and ALOX5 levels, and induced caspase-dependent cell apoptosis. Cells were treated with 0.5 umol/L DZNep for 72 h, and then whole-cell lysates were analyzed by Western-blot analysis. β-Actin was used as an internal control. Treatment with DZNep reduced protein levels of EZH2 in MM cells. ALOX5 was over-expressed in H929 and was down-regulated greatly by DZNep treatment. In H929 and MM1.S, DZNep efficiently induced caspase-3 activation and the cleavage of PARP. Furthermore, DZNep treatment induced caspase-8 activation and had little effect on full-length caspase-9 levels.
To understand the mechanisms of DZNep-induced cell death in MM cells, we examined the involvement of caspase in cell death. In NCI-H929 and MM.1S, DZNep efficiently induced caspase-3 activation and the cleavage of PARP, a substrate of caspase-3. Furthermore, DZNep treatment induced caspase-8 activation and had little effect on caspase-9 activation, suggesting DZNep might induce apoptosis via the death receptor signaling pathway.
Sensitivity to DZNep is modulated by expression levels of ALOX5
To investigate whether ALOX5 is directly associated with DZNep induced apoptosis, we generated the cell line of NCI-H929/ALOX5 overexpressing ALOX5. The proliferation assay indicated that overexpression of ALOX5 reduced sensitivity to DZNep and resulted in 3.2-fold increase of IC50 compared with vector control (Fig. 4A). To assay long-term effect of DZNep, we cultured control and NCI-H929/ALOX5 cells in methylcellulose with DZNep. NCI-H929/ALOX5 cells exhibited resistance to colony formation inhibition relative to control (Fig. 4B and Fig. S3A and S3B). Western-blot analysis showed a marked increase in the expression levels of ALOX5 in NCI-H929/ALOX5, and high levels of ectopic ALOX5 reduced PARP cleavage upon DZNep treatment (Fig. 4C). These data indicated that forced ectopic expression of ALOX5 could reduce sensitivity to DZNep.
()A NCI-H929 cells expressing the ectopic ALOX5 were treated with DZNep for 72 h. The proliferation was determined using the MTS colorimetric assay. * indicates p<0.05, and ** indicates p<0.01. (B) Colony formation assay. Cells were treated with DZNep and cultured in methylcellulose media for 14 days. Average colony counts are presented. Data represent the mean ± SD derived from 3 separate experiments with duplicate wells per condition. (C) Western-blot analysis. Cells were also infected with shRNA control or shALOX5. (D) After 72 h, total cell lysates were prepared and Western-blot analysis was performed. (E) Apoptosis was measured by flow cytometric sub-G1 analysis.The shALOX5 treatment induced apoptosis in NCI-H929, while it had little effect on DZNep resistance in KMS18.
To determine the effect of ALOX5 downregulation in cell viability, NCI-H929 was infected with the shALOX5. The shALOX5 mediated a significant decrease in ALOX5 mRNA and protein levels in NCI-H929 relative to a control shLuc (Fig. S2 and Fig. 4D). Similar to effect of DZNep, the shALOX5 also induced activation of caspase-8 and caspase-3 and cleavage of PARP, and had little effect on caspase-9 activation (Fig. 4D). Flow cytometric analysis indicated a significant increase of apoptosis after shALOX5 treatment in NCI-H929, while a minor increase in apoptosis was observed in control cell line KMS18 (Fig. 4E). Taken together, these data suggest that the downregulation of ALOX5 may contribute to cell viability of NCI-H929, and have the functional significance as a mediator of DZNep death response.
ALOX5 is aberrantly expressed in a subset of MM Patients
As DZNep induce apoptosis in myeloma cells in large parts through attenuating elevated expression of ALOX5, we wanted to see if ALOX5 is also aberrantly expressed in human MM. We assessed a large gene expression dataset from the University of Arkansas Medical School that is available through the Gene Expression Omnibus (GSE2658 and GSE5900), and found that ALOX5 expression was significantly higher in MM compared to NPC (p-value = 0.002). Taking mean+2SD as the upper limit of normal expression, 187 of 351 (53%) MM patients have abnormal elevated expression of ALOX5 (Fig. 5). This suggests that our finding in the myeloma cell lines is potentially applicable to a subset of MM patients.
Raw expression value was obtained from GEO GSE 2658 and 5900. The expression values for probes representing ALOX5 on the U133plus 2.0 chip were first log-transformed and median centered, and then a composite relative expression value for ALOX5 for each patient was obtained by taking the median expression across these probes. This relative expression value is represented on the Y axis. The expression value of 22 NPC and 351 newly diagnosed MM are highlighted ranked from low to high expression. The horizontal dotted line represents the mean +2SD expression value among the NPC.
Cotreatment with DZNep and ABT-737 synergistically inhibits growth and induces apoptosis of DZNep insensitive MM cells
Bcl-2 is widely expressed in MM cell lines and primary patient samples and is correlated with resistance to chemotherapeutics , , , . We hypothesize that Bcl-2 may also be associated with DZNep insensitivity in MM. As expected, elevated expression of Bcl-2 was detected in KMS18 and OPM-2 (Fig. 3). To see if inhibition of Bcl-2 can re-sensitize the resistant cells to DZNep, we determined the combined effects of DZNep and ABT-737, a Bcl-2 inhibitor, in MM cells. MTS assay demonstrated that, compared with each agent alone, combined treatment with DZNep and ABT-737 synergistically inhibited growth of KMS18 (DZNep at 0.25 or 0.5 µM/L) and OPM-2 cells, as indicated by combination indices of less than 1.0 (Fig. 6A, 6B, and Table 1). Colony formation assay indicated that KMS18 and OPM-2 cells exhibited a striking loss of colony formation upon cotreatment with DZNep and ABT-737 (Fig. 6C and Fig. S3C and S3D). In addition, cotreatment with DZNep and ABT-737 decreased Bcl-2 and bcl-xL levels, and induced more PARP cleavage in KMS18 and OPM-2 cells (Fig. 6D). ABT-737 treatment had little effect on Mcl-1 levels. This is consistent with a previous study that showed high affinity binding of ABT-737 to Bcl-2 and bcl-xL, but not to the less homologous protein Mcl-1 . In accordance with the synergistic effect of ABT-737 with DZNep, Bcl-2 shRNA treatment could also increase sensitivity to DZNep (Fig. S4),
(A) Analysis of dose-effect relationship for DZNep (500 nmol/L) and ABT-737 (500 or 1000 nmol/L) for the proliferation after 72 h of exposure in MM cells. The proliferation was determined by MTS colorimetric assay. Data represent the mean ± SD derived from 3 separate experiments with triplicate wells per condition. After this, the CI values were calculated. CI <1, CI = 1, and CI >1 represent synergy, additivity, and antagonism of the 2 agents, respectively. (B) Colony formation assay. Data represent the mean ± SD derived from 3 separate experiments with duplicate wells per condition. (C) After 72 h treatments, total cell lysates were prepared and Western-blot analysis was performed. (D) After treatment with ABT-737 for 48 h, Bcl-2 levels were determined by Western-blot. The Bcl-2 cleavage was inhibited by 1 h of preincubation with a pan-caspase inhibitor Z-VAD-FMK (Promega).
Previous reports showed ABT-737 disrupted an intracellular Bcl-2 family protein–protein interaction , while our western-blot analysis indicated ABT-737 could also induce Bcl-2 cleavage, represented by a small fragment recognized by Bcl-2 antibody. As Bcl-2 could be cleaved by caspases and cleavage of Bcl-2 could further activate downstream caspases , , and ABT-737 could induce activation of caspases in MM cell lines , , we examined whether ABT-737 induced Bcl-2 cleavage by a caspase-dependent pathway. As expected, cleavage of Bcl-2 induced by ABT-737 could be inhibited by pre-incubation with a pan-caspase inhibitor Z-VAD-FMK (Fig. 6E).
DZNep was previously reported to be a selective inhibitor of H3K27 and H4K20 trimethylation . The extended study showed that DZNep globally inhibited histone methylation and was not selective . Because there are multiple epigenetic mechanisms that deregulate gene expression during carcinogenesis, a molecule such as DZNep that inhibits multiple marks may be useful in epigenetic therapy.
MM is an incurable hematologic malignancy characterized by recurrent chromosomal translocations , . MMSET (multiple myeloma SET domain) was identified as a gene involved in the t(4;14)(p16;q32) translocation affecting approximately 15% patients , . This subtype of myeloma has a poor prognosis with frequent relapse after autologous stem-cell transplantation , , . MMSET contains a SET domain that is found in many histone methyltransferases and determines their enzymatic activity. MMSET has been shown to be a transcriptional corepressor and increase H4K20 trimethylation , so we hypothesized that DZNep should be useful for epigenetic therapy against MM with t(4;14). However, our proliferation and apoptosis assays indicated DZNep sensitivity was not associated with t(4;14) in MM (Table S5). In addition, the sensitivity of myeloma cells to DZNep is not directly related to inhibition of EZH2 or H3K27 trimethylation, suggesting the DZNep may also act through non-epigenetic mechanisms. The precise mechanism of drug activity in myeloma remains elusive and is being actively pursued by our group.
Nevertheless, insights into the determinants of DZNep sensitivity was derived from gene expression array analysis of MM cells treated with vehicle control or DZNep. Transcripts differentially expressed in response to DZNep in MM were remarkably enriched for their roles in cellular metabolism, suggesting cellular metabolism might play a vital role in MM cell sensitivity to DZNep induced apoptosis. Previous studies showed that metabolic pathways are not only involved in the proliferation of cancer cells, but also regulated their apoptosis . ALOX5, the most down-regulated gene by DZNep in sensitive MM cells, is a member of the lipoxygenase gene family and plays an essential role in the biosynthesis of leukotrienes from arachidonic acid . Several groups have examined the role of ALOX5 pathway in carcinogenesis and have shown that it plays an important role in promoting tumor growth and survival , , , , . Recently it was shown that the loss of ALOX5 gene impaired leukemia stem cells and prevented chronic myeloid leukemia in mice . These prompted us to determine whether overexpression of ALOX5 is associated with DZNep sensitivity. Our studies indicated DZNep treatment could decrease ALOX5 level, and ectopic expression of ALOX5 reduced sensitivity to DZNep in NCI-H929. Furthermore, knocking down ALOX5 could also induce apoptosis with activation of caspases. These results suggest that ALOX5 has the functional significance as a mediator of DZNep induced apoptosis. However, ectopic expression of ALOX5 incompletely prevents NCI-H929 cells from DZNep induced apoptosis, so the apoptosis might depend on the change of multiple proteins or signaling pathways. Several striking differences such as FADS1 and SCD5 involved in cellular metabolism were also observed in DZNep sensitive cell lines in addition to the changes in ALOX5 (Table S2).
The overexpression of Bcl-2 is almost universal in MM cell lines and primary patient samples and promotes inappropriate survival leading to resistance to therapy with interferon, dexamethasone, etoposide, doxorubicin and bortezomib, , , . ABT-737 is a small-molecule inhibitor designed to specifically inhibit antiapoptotic proteins of the Bcl-2 family. This molecule is a BH3 (Bcl-2 homology region 3) mimetic that binds with high affinity to Bcl-xL, Bcl-2 and Bcl-w. Binding of ABT-737 to a hydrophobic groove on Bcl-2 family proteins prevents binding of Bax, tilting the balance of pro- and antiapoptotic molecules in favor of cellular apoptosis , . Previous studies reveal that ABT-737 synergizes with a range of cytotoxic chemotherapy agents , , . We found that Bcl-2 was overexpressed in DZNep insensitive cell lines and combined treatment with DZNep and ABT-737 synergistically induced apoptosis in these cells. This also suggested that overexpression of Bcl-2 might be associated with DZNep insensitivity. Although ABT-737 inhibits antiapoptotic functions of Bcl-2 family through competing with BAD for docking to the hydrophobic groove of Bcl-2/Bcl-xL, thus increasing activity of pro-apoptotic BH3 proteins, we found that ABT-737 could also promote Bcl-2 cleavage, represented by a small fragment recognized by Bcl-2 antibody through a caspase dependent pathway.
In conclusion, this study showed that one of the determinants of DZNep efficacy in MM is the ability to down-regulate elevated ALOX5 levels. As ALOX5 is over-expressed in a substantial subset of MM patients, this may be is viable therapeutic strategy in a subset of MM. In addition, DZNep insensitivity might be associated with the overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis in DZNep insensitive MM.
The cDNA microarray analysis of gene expression changes in response to DZNep treatment. (A) The column diagram showing the numbers of differentially expressed genes in DZNep-treated cell lines. Much more number of transcripts were differentially expressed in response to DZNep in sensitive cell lines than in insensitive cell lines. (B) Gene ontology (GO) assignments of biological process of genes. GO analysis revealed that these genes were remarkably enriched for their roles in cellular metabolism.
NCI-H929 cells were infected with shRNA control or shALOX5. After 48 h, ALOX5 mRNA level was analyzed by quantitative RT-PCR.
Colony formation assay in methylcellulose media. Cells were plated in duplicate at a density of 1,500 or 3,000 cells/mL in 0.4 mL volume in 24-well plates. Plates were incubated at 37°C, 5% CO2, and ≥95% humidity for 14 days. To observe colonies, cells were stained with 0.5 mg/mL metabolizable tetrazolium salt. After incubating at 37°C, 5% CO2 for 1 h, images were acquired at 40X magnification with an Olimpus IX71 inverted microscope. Each experiment was performed 3 times, and representative examples are shown. (A) and (B) Ectopic expression of ALOX5 reduced sensitivity to DZNep. (C) and (D) Cotreatment with DZNep and ABT-737 synergistically reduced colony formation in KMS18 and OPM-2.
Potentiation effect of Bcl-2 shRNA with DZNep in KMS18 and OPM-2 MM cells. Cells were treated with Bcl-2 shRNAs and cultured for 3 days with or without DZNep treatment. Luc, control shRNA; #82 and #83, Bcl-2 shRNA. (A) and (B) Bcl-2 shRNAs increased sensitivity to DZNep. The proliferation was determined by MTS colorimetric assay (Promega). Data represent the mean ± SD derived from 3 separate experiments with triplicate wells per condition. (C) Quantitative RT-PCR analysis of Bcl-2 mRNA level on 48 h of Bcl-2 shRNA treatment. Colunms, mean; bars, SE. Average CT values were first normalized against the housekeeping gene β-Actin and converted to the induced fold change relative to the vehicle control. (D) Western-blot analysis of apoptosis and Bcl-2 expression.
Primer Sequences for quantitative PCR.
Specially differentially expressed genes (fold changes >2) in sensitive MM cell lines (H929 and MM1.S) exposed to DZNep.
Specially differentially expressed genes (fold changes >2) in insensitive MM cell lines (KMS18 and OPM-2) exposed to DZNep.
Common differentially expressed genes (fold changes >2) in MM cell lines exposed to DZNep.
Conceived and designed the experiments: ZX WJC. Performed the experiments: ZX CB LLC SCL WJC. Analyzed the data: ZX CB GH JZ WJC. Contributed reagents/materials/analysis tools: QY C-SC. Wrote the paper: ZX WJC.
- 1. Glazer RI, Knode MC, Tseng CK, Haines DR, Marquez VE (1986) 3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem Pharmacol 35: 4523–4527.RI GlazerMC KnodeCK TsengDR HainesVE Marquez19863-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells.Biochem Pharmacol3545234527
- 2. Glazer RI, Hartman KD, Knode MC, Richard MM, Chiang PK, et al. (1986) 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 135: 688–694.RI GlazerKD HartmanMC KnodeMM RichardPK Chiang19863-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60.Biochem Biophys Res Commun135688694
- 3. Bray M, Driscoll J, Huggins JW (2000) Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 45: 135–147.M. BrayJ. DriscollJW Huggins2000Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor.Antiviral Res45135147
- 4. De Clercq E, Cools M, Balzarini J, Marquez VE, Borcherding DR, et al. (1989) Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-nor derivatives. Antimicrob Agents Chemother 33: 1291–1297.E. De ClercqM. CoolsJ. BalzariniVE MarquezDR Borcherding1989Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-nor derivatives.Antimicrob Agents Chemother3312911297
- 5. Mayers DL, Mikovits JA, Joshi B, Hewlett IK, Estrada JS, et al. (1995) Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3′-azido-3′-deoxythymidine-resistant HIV-1 strains. Proc Natl Acad Sci U S A 92: 215–219.DL MayersJA MikovitsB. JoshiIK HewlettJS Estrada1995Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3′-azido-3′-deoxythymidine-resistant HIV-1 strains.Proc Natl Acad Sci U S A92215219
- 6. Tan J, Yang X, Zhuang L, Jiang X, Chen W, et al. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050–1063.J. TanX. YangL. ZhuangX. JiangW. Chen2007Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.Genes Dev2110501063
- 7. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, et al. (2009) Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733–2743.W. FiskusY. WangA. SreekumarKM BuckleyH. Shi2009Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.Blood11427332743
- 8. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.DM ParkinF. BrayJ. FerlayP. Pisani2005Global cancer statistics, 2002.CA Cancer J Clin5574108
- 9. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (2009) Multiple myeloma. Lancet 374: 324–339.MS RaabK. PodarI. BreitkreutzPG RichardsonKC Anderson2009Multiple myeloma.Lancet374324339
- 10. Xie Z, Choong PF, Poon LF, Zhou J, Khng J, et al. (2008) Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 62: 949–957.Z. XiePF ChoongLF PoonJ. ZhouJ. Khng2008Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion.Cancer Chemother Pharmacol62949957
- 11. Zhou J, Pan M, Xie Z, Loh SL, Bi C, et al. (2008) Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 22: 138–146.J. ZhouM. PanZ. XieSL LohC. Bi2008Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.Leukemia22138146
- 12. Ozvaran MK, Cao XX, Miller SD, Monia BA, Hong WK, et al. (2004) Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Ther 3: 545–550.MK OzvaranXX CaoSD MillerBA MoniaWK Hong2004Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.Mol Cancer Ther3545550
- 13. Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1: 1458–1461.C. RiccardiI. Nicoletti2006Analysis of apoptosis by propidium iodide staining and flow cytometry.Nat Protoc114581461
- 14. Mi H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, et al. (2005) The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res 33: D284–288.H. MiB. Lazareva-UlitskyR. LooA. KejariwalJ. Vandergriff2005The PANTHER database of protein families, subfamilies, functions and pathways.Nucleic Acids Res33D284288
- 15. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, et al. (2004) p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 279: 21183–21192.PS KhoZ. WangL. ZhuangY. LiJL Chew2004p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis.J Biol Chem2792118321192
- 16. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, et al. (2008) Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134: 62–73.S. GodarTA InceGW BellD. FeldserJL Donaher2008Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression.Cell1346273
- 17. Belfiore MC, Natoni A, Barzellotti R, Merendino N, Pessina G, et al. (2007) Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells. Cancer Lett 254: 236–243.MC BelfioreA. NatoniR. BarzellottiN. MerendinoG. Pessina2007Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells.Cancer Lett254236243
- 18. Chen Y, Hu Y, Zhang H, Peng C, Li S (2009) Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 41: 783–792.Y. ChenY. HuH. ZhangC. PengS. Li2009Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.Nat Genet41783792
- 19. Ghosh J (2003) Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem Biophys Res Commun 307: 342–349.J. Ghosh2003Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase.Biochem Biophys Res Commun307342349
- 20. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, et al. (2008) Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 14: 6525–6530.LG MelstromDJ BentremMR SalabatTJ KennedyXZ Ding2008Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model.Clin Cancer Res1465256530
- 21. Zhou GX, Ding XL, Huang JF, Zhang H, Wu SB (2007) Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines. Biochim Biophys Acta 1770: 1021–1027.GX ZhouXL DingJF HuangH. ZhangSB Wu2007Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines.Biochim Biophys Acta177010211027
- 22. Puthier D, Derenne S, Barille S, Moreau P, Harousseau JL, et al. (1999) Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol 107: 392–395.D. PuthierS. DerenneS. BarilleP. MoreauJL Harousseau1999Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.Br J Haematol107392395
- 23. Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost A, et al. (1995) Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer 63: 190–192.O. SangfeltA. OsterborgD. GranderE. AnderbringA. Ost1995Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein.Int J Cancer63190192
- 24. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, et al. (1999) Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93: 3044–3052.R. FeinmanJ. KouryM. ThamesB. BarlogieJ. Epstein1999Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.Blood9330443052
- 25. Tu Y, Xu FH, Liu J, Vescio R, Berenson J, et al. (1996) Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 88: 1805–1812.Y. TuFH XuJ. LiuR. VescioJ. Berenson1996Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide.Blood8818051812
- 26. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677–681.T. OltersdorfSW ElmoreAR ShoemakerRC ArmstrongDJ Augeri2005An inhibitor of Bcl-2 family proteins induces regression of solid tumours.Nature435677681
- 27. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, et al. (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278: 1966–1968.EH ChengDG KirschRJ ClemR. RaviMB Kastan1997Conversion of Bcl-2 to a Bax-like death effector by caspases.Science27819661968
- 28. Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, et al. (1999) Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 274: 21155–21161.DG KirschA. DoseffBN ChauDS LimNC de Souza-Pinto1999Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c.J Biol Chem2742115521161
- 29. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, et al. (2007) ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21: 1549–1560.MP KlineSV RajkumarMM TimmTK KimlingerJL Haug2007ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.Leukemia2115491560
- 30. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, et al. (2007) A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26: 2374–2380.D. ChauhanM. VelankarM. BrahmandamT. HideshimaK. Podar2007A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.Oncogene2623742380
- 31. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, et al. (2009) DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 8: 1579–1588.TB MirandaCC CortezCB YooG. LiangM. Abe2009DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.Mol Cancer Ther815791588
- 32. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, et al. (1996) Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A 93: 13931–13936.PL BergsagelM. ChesiE. NardiniLA BrentsSL Kirby1996Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.Proc Natl Acad Sci U S A931393113936
- 33. Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23: 6333–6338.PL BergsagelWM Kuehl2005Molecular pathogenesis and a consequent classification of multiple myeloma.J Clin Oncol2363336338
- 34. Keats JJ, Reiman T, Belch AR, Pilarski LM (2006) Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 47: 2289–2300.JJ KeatsT. ReimanAR BelchLM Pilarski2006Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.Leuk Lymphoma4722892300
- 35. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, et al. (1998) The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92: 3025–3034.M. ChesiE. NardiniRS LimKD SmithWM Kuehl1998The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.Blood9230253034
- 36. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, et al. (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101: 1520–1529.JJ KeatsT. ReimanCA MaxwellBJ TaylorLM Larratt2003In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.Blood10115201529
- 37. Chang H, Sloan S, Li D, Zhuang L, Yi QL, et al. (2004) The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 125: 64–68.H. ChangS. SloanD. LiL. ZhuangQL Yi2004The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.Br J Haematol1256468
- 38. Dillon SC, Zhang X, Trievel RC, Cheng X (2005) The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol 6: 227.SC DillonX. ZhangRC TrievelX. Cheng2005The SET-domain protein superfamily: protein lysine methyltransferases.Genome Biol6227
- 39. Marango J, Shimoyama M, Nishio H, Meyer JA, Min DJ, et al. (2008) The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 111: 3145–3154.J. MarangoM. ShimoyamaH. NishioJA MeyerDJ Min2008The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.Blood11131453154
- 40. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134: 703–707.PP HsuDM Sabatini2008Cancer cell metabolism: Warburg and beyond.Cell134703707
- 41. Peters-Golden M (1998) Cell biology of the 5-lipoxygenase pathway. Am J Respir Crit Care Med 157: S227-231; discussion S231-222, S247-228: M. Peters-Golden1998Cell biology of the 5-lipoxygenase pathway.Am J Respir Crit Care Med 157: S227-231; discussion S231-222,S247-228
- 42. Ghosh J, Myers CE (1998) Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A 95: 13182–13187.J. GhoshCE Myers1998Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells.Proc Natl Acad Sci U S A951318213187
- 43. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, et al. (2009) The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23: 2034–2041.KD MasonSL KhawKC RayerouxE. ChewEF Lee2009The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.Leukemia2320342041
- 44. Pandit B, Gartel AL (2010) New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. Prostate 70: 825–833.B. PanditAL Gartel2010New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.Prostate70825833